awmsg logo



lisdexamfetamine dimesylate (Elvanse Adult®)


Reference No. 2534

Publication date:
13/10/2015


Appraisal information

lisdexamfetamine dimesylate (Elvanse Adult®) 30 mg capsule
lisdexamfetamine dimesylate (Elvanse Adult®) 50 mg capsule
lisdexamfetamine dimesylate (Elvanse Adult®) 70 mg capsule


Company: Shire Pharmaceuticals Ltd
BNF category: Central nervous system
NMG meeting date: 22/07/2015
AWMSG meeting date: 16/09/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2615
Ministerial ratification: 09/10/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Lisdexamfetamine dimesylate (Elvanse Adult®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download